BACKGROUND: Surgical injury induces production and release of inflammatory mediators in the vicinity of the wound. They in turn trigger nociceptive signaling to produce hyperalgesia and pain. Interleukin-1β plays a crucial role in this process. The mechanism regulating production of this cytokine after incision is, however, unknown. Caspase-1 is a key enzyme that cleaves prointerleukin-1β to its active form. We hypothesized that caspase-1 is a crucial regulator of incisional interleukin-1β levels, nociceptive sensitization, and inflammation. METHODS: These studies employed a mouse hind paw incisional model. Caspase-1 was blocked using the selective inhibitors Ac-YVAD-CMK and VRTXSD727. Nociceptive sensitization, edema, and hind paw warmth were followed in intact animals whereas caspase-1 activity, cytokine, and prostaglandin E2 levels were assessed in homogenized skin. Confocal microscopy was used to detect the expression of caspase-1 near the wounds. RESULTS: Analysis of enzyme activity demonstrated that caspase-1 activity was significantly increased in periincisional skin. Pretreatment with Ac-YVAD-CMK significantly reduced mechanical allodynia and thermal hyperalgesia. Repeated administration of this inhibitor produced robust analgesia, especially to mechanical stimulation. Administration of VRTXSD727 provided qualitatively similar results. Caspase-1 inhibition also reduced edema and the normally observed increase in paw warmth around the wound site. Correspondingly, caspase-1 inhibition significantly reduced interleukin-1β as well as macrophage-inflammatory protein 1α, granulocyte colony-stimulating factor, and prostaglandin E2 levels near the wound. The expression of caspase-1 was primarily observed in keratinocytes in the epidermal layer and in neutrophils deeper in the wounds. CONCLUSIONS: The current study demonstrates that the inhibition of caspase-1 reduces postsurgical sensitization and inflammation, likely through a caspase-1/interleukin-1β-dependent mechanism.
BACKGROUND: Surgical injury induces production and release of inflammatory mediators in the vicinity of the wound. They in turn trigger nociceptive signaling to produce hyperalgesia and pain. Interleukin-1β plays a crucial role in this process. The mechanism regulating production of this cytokine after incision is, however, unknown. Caspase-1 is a key enzyme that cleaves prointerleukin-1β to its active form. We hypothesized that caspase-1 is a crucial regulator of incisional interleukin-1β levels, nociceptive sensitization, and inflammation. METHODS: These studies employed a mouse hind paw incisional model. Caspase-1 was blocked using the selective inhibitors Ac-YVAD-CMK and VRTXSD727. Nociceptive sensitization, edema, and hind paw warmth were followed in intact animals whereas caspase-1 activity, cytokine, and prostaglandin E2 levels were assessed in homogenized skin. Confocal microscopy was used to detect the expression of caspase-1 near the wounds. RESULTS: Analysis of enzyme activity demonstrated that caspase-1 activity was significantly increased in periincisional skin. Pretreatment with Ac-YVAD-CMK significantly reduced mechanical allodynia and thermal hyperalgesia. Repeated administration of this inhibitor produced robust analgesia, especially to mechanical stimulation. Administration of VRTXSD727 provided qualitatively similar results. Caspase-1 inhibition also reduced edema and the normally observed increase in paw warmth around the wound site. Correspondingly, caspase-1 inhibition significantly reduced interleukin-1β as well as macrophage-inflammatory protein 1α, granulocyte colony-stimulating factor, and prostaglandin E2 levels near the wound. The expression of caspase-1 was primarily observed in keratinocytes in the epidermal layer and in neutrophils deeper in the wounds. CONCLUSIONS: The current study demonstrates that the inhibition of caspase-1 reduces postsurgical sensitization and inflammation, likely through a caspase-1/interleukin-1β-dependent mechanism.
Authors: Waldiceu A Verri; Thiago M Cunha; Carlos A Parada; Stephen Poole; Fernando Q Cunha; Sérgio H Ferreira Journal: Pharmacol Ther Date: 2006-05-30 Impact factor: 12.310
Authors: Kim A Boost; Sandra Hoegl; Christian Hofstetter; Michael Flondor; Klaus Stegewerth; Ilka Platacis; Josef Pfeilschifter; Heiko Muhl; Bernhard Zwissler Journal: Intensive Care Med Date: 2007-03-24 Impact factor: 17.440
Authors: Woods Wannamaker; Robert Davies; Mark Namchuk; John Pollard; Pamella Ford; George Ku; Caroline Decker; Paul Charifson; Peter Weber; Ursula A Germann; Keisuke Kuida; John C R Randle Journal: J Pharmacol Exp Ther Date: 2007-02-08 Impact factor: 4.030
Authors: M Danilo Boada; Silvia Gutierrez; Kelly Giffear; James C Eisenach; Douglas G Ririe Journal: J Neurophysiol Date: 2012-06-06 Impact factor: 2.714
Authors: Reno Roberts; Mark J Wall; Ingke Braren; Karendeep Dhillon; Amy Evans; Jack Dunne; Simbarashe Nyakupinda; Robert T R Huckstepp Journal: Front Aging Neurosci Date: 2022-06-29 Impact factor: 5.702
Authors: M Danilo Boada; Silvia Gutierrez; Carol A Aschenbrenner; Timothy T Houle; Ken-Ichiro Hayashida; Douglas G Ririe; James C Eisenach Journal: J Neurophysiol Date: 2014-10-01 Impact factor: 2.974